← All Denali Therapeutics INC filings

Denali Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
DNLI
Denali Therapeutics INC
10-K: Denali Therapeutics Navigates Pipeline Progress, Financial Headwinds
Denali Therapeutics reports increased net losses in 2025, alongside significant clinical advancements for its TransportVehicle platform and key program updates, including a PDUFA extension for tividenofusp alfa.
NASDAQ
DNLI
Denali Therapeutics INC
10-K: Denali Therapeutics (DNLI) Files 10-K: BLA Submission Planned for Hunter Syndrome Drug
Denali Therapeutics plans to submit a BLA for its Hunter Syndrome drug in early 2025 and is preparing for a potential commercial launch.
NASDAQ
DNLI
Denali Therapeutics INC
10-K: Denali Therapeutics 10-K Filing: Focus on Brain Delivery and Neurodegenerative Diseases
Denali Therapeutics' 10-K filing highlights its focus on developing therapies for neurodegenerative and lysosomal storage diseases using its proprietary blood-brain barrier crossing technology.